Next-Generation Transformable Nanomedicines: Revolutionizing Cancer Drug Delivery and Theranostics
Molecular Pharmaceutics · 02.06.2025 · 22 (6) · 2783-2806
DOI: 10.1021/acs.molpharmaceut.4c01495 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 03.05.2025. Verfasst von Swapnil Shinde und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Res…. Hauptthemen laut MEDLINE: Neoplasms, Theranostic Nanomedicine, Drug Delivery Systems, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 144 Literaturangaben.
Abstract (Originalsprache)
Nanomedicine has significantly advanced the treatment of various cancer phenotypes, addressing numerous challenges associated with conventional therapies. Researchers have extensively investigated the physicochemical properties of nanocarriers, such as charge, morphology, and surface chemistry, to optimize drug delivery systems. In the context of transformable nanomedicine, these properties are particularly critical for overcoming existing limitations, including suboptimal blood circulation times, sequestration by the reticuloendothelial system and mononuclear phagocyte system, and inefficient targeting of the tumor microenvironment (TME). Alterations in nanocarrier geometry, surface charge, and hydrophilicity have shown potential in mitigating these barriers, offering improved therapeutic outcomes and enhanced biomedical applications. This review explores controlled modulation of these properties in the context of anticancer therapy, offering an in-depth exploration of transformable strategies activated by both internal and external stimuli. We analyze the implications of these tunable characteristics on pharmacokinetics, biodistribution, and targeted delivery to the TME. Additionally, we address the current challenges in the clinical translation of these advanced nanocarriers and propose strategies to overcome these obstacles to enhance the clinical feasibility of nanomedicine-based cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
ORCID-Profile: Saurabh Srivastava
Zitieren
APA
Shinde, S., Shah, S., Famta, P., Wagh, S., Pandey, G., Sharma, A., Vambhurkar, G., Jain, A., & Srivastava, S. (2025). Next-Generation Transformable Nanomedicines: Revolutionizing Cancer Drug Delivery and Theranostics. Molecular Pharmaceutics, 22(6), 2783-2806. https://doi.org/10.1021/acs.molpharmaceut.4c01495
Vancouver
Shinde S, Shah S, Famta P, Wagh S, Pandey G, Sharma A, et al. Next-Generation Transformable Nanomedicines: Revolutionizing Cancer Drug Delivery and Theranostics. Molecular Pharmaceutics. 2025;22(6):2783-2806. doi:10.1021/acs.molpharmaceut.4c01495
BibTeX
@article{Shinde2025,
author = {Shinde, Swapnil and Shah, Saurabh and Famta, Paras and Wagh, Suraj and Pandey, Giriraj and Sharma, Abhishek and Vambhurkar, Ganesh and Jain, Akshita and Srivastava, Saurabh},
title = {Next-Generation Transformable Nanomedicines: Revolutionizing Cancer Drug Delivery and Theranostics},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {6},
pages = {2783--2806},
doi = {10.1021/acs.molpharmaceut.4c01495}
}
EUVIMED